References

  1. Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Research and Therapy. 2012; 9(31). PubMed | Google Scholar

  2. Federal Democratic Republic of Ethiopia .Federal HIV/AIDS Prevention and control Office. Guidelines for Implementation of HIV/AIDS Case Management in Ethiopia, Addis Ababa, Ethiopia. 2009; P 1. PubMed | Google Scholar

  3. Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infectious Diseases. 2012; 12(197). PubMed | Google Scholar

  4. Federal Democratic Republic of Ethiopia. Country progress report on HIV/AIDS response. Ministry of Health, Addis Ababa, Ethiopia. 2012. Google Scholar

  5. Federal Democratic Republic of Ethiopian. Ministry Of Health. Health sector development programme IV version 1 annual performance report. Addis Ababa, Ethiopia. 2010/2011; P 28 & 30. Google Scholar

  6. Charles M, Leger P, Severe P, Guiteau C, Apollon A, Gulick R et al. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti.Journal of the International AIDS Society.2012; 15 (2):173-75. PubMed | Google Scholar

  7. Jonathan Z. Minority HIV-1 Drug Resistance Mutations and the Risk of NNRTI-based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis. Journal of American medical association.2011; 305 (13): 1327-1335. PubMed | Google Scholar

  8. Khienprasit N, Chaiwarith R, Sirisanthana T and SupparatpinyoK. Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Research and Therapy. 2011; 8(1):42. PubMed | Google Scholar

  9. Kassa D, Gebremichael G, Alemayehu Y, Wolday D, Messele T and Baarle D. Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia. AIDS Research and Therapy. 2013; 1742(6405):10-18. PubMed | Google Scholar

  10. Liaoa L, Xinga H, Sub B, Wangc Z, Ruana Y, Wanga X et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. AIDS. 2013; 27(11):1815-24. PubMed | Google Scholar

  11. Ma Y, Zhao D, Yu L, Bulterys M, Robinson M, Zhao Y et al. Predictors of virologic failure in HIV-1-infected adults on first line antiretroviral therapy in eight provinces in China. Clinical Infectious Diseases. 2010; 50(2):264-71. PubMed | Google Scholar

  12. Singh A, Agarwal A, Chakravarty J, kumari S, Rai M et al. Predictive Markers of Failure of First Line Anti Retroviral Treatment in HIV Patients in India. J AIDS Clin Res . 2013; 4(210). PubMed | Google Scholar

  13. Ferreyra C, Yun O, Eisenberg N, Alonso E, Khamadi A, Mwau M et al. Evaluation of Clinical and Immunological Markers for Predicting Virological Failure in a HIV/AIDS Treatment Cohort in Busia, Kenya. PLoS ONE. 2012; 7(11):e49834. PubMed | Google Scholar

  14. ElmiAbar A, Jlizi A, Youssouf H, Ali M, Hadj B and Slim A. HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.Diagnostic Pathology. 2012; 7(138). PubMed | Google Scholar

&